SCHEMBL25324178

SCHEMBL25324178

CCOc1ccc(OCC)c2c1sc1nncn12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS2 Q9H2K2 16/20 0.67
▸ PARP15 Q460N3 15/20 0.67
▸ PARP2 Q9UGN5 15/20 0.67
▸ PARP10 Q53GL7 14/20 0.67
▸ BRPF1 P55201 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ PARP14 Q460N5 2/20 0.36
▸ TNKS O95271 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ PARP6 Q2NL67 1/20 0.35
▸ TIPARP Q7Z3E1 1/20 0.35
▸ PARP16 Q8N5Y8 1/20 0.35
▸ PARP12 Q9H0J9 1/20 0.35
▸ PARP11 Q9NR21 1/20 0.35
▸ PARP4 Q9UKK3 1/20 0.35
▸ PARP3 Q9Y6F1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25325363 0.80 PARP2 (1.00) TNKS2PARP15PARP2PARP10BRPF1
SCHEMBL25323641 0.72 PARP2 (0.68) TNKS2PARP15PARP2PARP10KDM4E
SCHEMBL25324694 0.67 TNKS2 (0.78) TNKS2PARP15PARP2PARP10BRPF1
SCHEMBL25324686 0.64 TNKS2 (1.00) TNKS2PARP15PARP2PARP10BRPF1
SCHEMBL25323644 0.63 TNKS2 (1.00) TNKS2PARP15PARP2PARP10BRPF1
SCHEMBL6402519 0.59 KDM4E (0.41) KDM4EHSD17B10MAPK1ALDH1A1HPGD
SCHEMBL25323210 0.59 TNKS2 (0.63) TNKS2PARP15PARP2PARP10BRPF1
SCHEMBL25323203 0.59 TNKS2 (1.00) TNKS2PARP15PARP2PARP10KDM4E
SCHEMBL25323852 0.57 KDM4E (0.68) KDM4EHSD17B10MAPK1ALDH1A1HPGD
SCHEMBL25324784 0.57 TNKS2 (1.00) TNKS2PARP15PARP2PARP10BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2025-06-05 — — US disclosed
EP-4469046-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS Oulun Yliopisto (FI) 2024-12-04 — — EP disclosed
WO-2023144450-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2023-08-03 — — WO disclosed
WO-2023144450-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS OULUN YLIOPISTO (FI) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177359-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS NAMPT, NADK, NQO1 TNKS2 29/4885PARP15 9/4885PARP2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback